Targeted therapeutics against this IFN-driven cascade, such as anifrolumab, have been shown to be viable treatment options in reducing the burden of refractory cutaneous disease associated with SLE.7, 8, 9 This series adds to growing number of descriptions documenting the efficacy of anifrolumab in treating recalcitrant CLE. Here, IFNA1 is linked to systemic lupus erythematosus.